RapidAI Secures $75M in Series C Funding

Stroke is the second-leading cause of death worldwide, claims approximately 137,000 lives in the U.S. every year. The urgent need for technology that ensures quick and precise assessment of this critical health condition.

Enter RapidAI. Established in 2012, the company's software aims to aid hospitals in managing their heavy imaging workload.

Recent milestones demonstrating RapidAI’s platform innovation and market traction include:

• Surpassed 10 million scans analyzed on the platform;
• Published in over 300 peer reviewed publications;
• Deployed in over 2,200 hospitals in 100+ countries; and
• Leveraged in over 25 clinical trials.

Hospitals are increasingly looking for RapidAI solutions to solve their critical needs, including helping care teams work more efficiently and support clinical decision making for better patient outcomes - said Karim Karti, CEO of RapidAI

Funding led by: Vista Credit Partners (a subsidiary of Vista Equity Partners)

Total Funding Amount: $75M

Sector: HealthTech

Funds Use: The company will deploy the funds to support additional disease states, strengthen go-to-market functions, and speed up expansion in new regions and product categories.

About: RapidAI develops AI solutions aimed at combating life-threatening neurovascular, cardiac, and vascular diseases.